Philip Larsen
CEO Antag Therapeutics
Philip Larsen is the CEO of SixPeaks Bio, a company focused on next-generation therapies for obesity and metabolic diseases. With over two decades of executive experience in global pharmaceutical R&D, he has led therapeutic innovation from discovery through clinical proof-of-concept. His previous roles include Senior Vice President and Global Head of Research & Early Development at Bayer Pharmaceuticals, where he oversaw therapeutic innovation. Philip holds an MD and PhD from the University of Copenhagen and has a strong background in neuroscience. His expertise spans obesity therapeutics, incretin biology, and metabolic target validation, underpinned by a track record of advancing molecules from bench to bedside.
Seminars
Thursday 16th July 2026
Engineering “Healthy Weight Loss” to Redefine Metabolic Quality via Precision Antibody-Peptide Conjugates (APCs) to Prevent Sarcopenia
11:30 am
- Utilizing an Activin IIA/B bispecific antibody to lift the “biological brake” on muscle growth, addressing the critical limitation of current GLP-1s where up to 40% of weight loss is derived from lean muscle mass
- Matching the fat-loss potency of high-dose injectables while simultaneously driving muscle hypertrophy, offering a “best-in-class” body composition profile that accelerates adipose-specific weight loss and boosts basal energy expenditure
- Optimizing the pharmacokinetic profile of lead candidate SPX-001 and its GLP-1 conjugates to ensure stable, monthly dosing that preserves metabolic fitness, prevents weight regain “rebound,” and provides a durable foundation for long-term cardiometabolic health
